Vi Polysaccharide Vaccine

BIOLOGICAL3 trials

Sponsors

PT Bio Farma

Conditions

ImmunogenicitySafety Issues

Phase 1

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

CompletedNCT03109600

PT Bio FarmaSafety Issues

Start: 2017-04-18End: 2018-02-19Updated: 2018-03-06

Phase 2

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

CompletedNCT03460405

PT Bio FarmaImmunogenicity, Safety Issues

Start: 2018-07-16End: 2020-01-30Updated: 2020-02-20

Phase 3

Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

CompletedNCT04051268

PT Bio FarmaImmunogenicity, Safety Issues

Start: 2020-03-02End: 2021-12-01Updated: 2022-01-04

Related Papers

One-month evaluation of safety and immunogenicity of a Vi-DT typhoid conjugate vaccine (Bio-TCV®) in Indonesian subjects 6 months to 45 years: A phase III randomized clinical trial

Vaccine X2025-05-201 citations

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity

Tropical Diseases Travel Medicine and Vaccines2024-02-014 citations

A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report

BMC Pediatrics2020-10-1516 citations

One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine

International Journal of Infectious Diseases2020-01-2815 citations